Latest Biotech News

Researchers reported wearable sensor technology designed to distinguish walking and non-walking behaviors as a measurable marker of Parkinson’s progression, aiming to improve early to mid-stage...

A new adenine base editing strategy reported in Gene Therapy corrected a splice mutation (IVS4+919; G>A) linked to cardiac-type Fabry disease in cells. The work centers on using ABE to restore the...

Roche said it is escalating its push for EMA approval of its Duchenne muscular dystrophy gene therapy, Elevidys (delandistrogene moxeparvovec), by announcing a further global Phase 3 trial. The...

Teams at the University of Pittsburgh and UPMC reported results from a first-in-human approach that trains the immune system to accept donor livers. The program uses donor-specific immune...

UCB agreed to buy Neurona for up to $1.2 billion, aiming to expand beyond its small-molecule epilepsy portfolio into seizure cell therapy. UCB said the deal helps diversify its pipeline with a...

Kailera Therapeutics priced an upsized IPO to raise $625 million, positioning it among the largest U.S. biotech debuts and funding a pipeline of injectable and oral obesity candidates licensed...

Neomorph closed a $100 million Series B to advance its lead molecular glue degrader, NEO-811, through a Phase I/II study. The oral therapy is designed to induce targeted degradation of ARNT...

Transformative Biotech unveiled plans built around extraction-free PCR chemistry designed to remove one of the main bottlenecks in molecular testing. The company says its patented buffer chemistry...

Beeline Medicines launched with five programs licensed from Bristol Myers Squibb and secured a $300 million Series A led by Bain Capital. Its lead asset, afimetoran, is a once-daily oral selective...

New BioSpace tallies show fewer biopharma layoffs or projected cuts in Q1 2026 versus Q1 2025, though total affected employees increased, driven largely by Viatris’ plan to reduce up to 10% of its...

FDA is moving toward easing restrictions on certain compounded peptides after signaling it will convene outside advisers to reassess whether some U.S. pharmacies should be allowed to manufacture...

Kailera Therapeutics priced an upsized U.S. IPO to raise $625 million, positioning the company among the largest-ever biotech debuts while funding a pipeline of injectable and oral obesity...

Eli Lilly reported positive cardiovascular safety results for Foundayo (orforglipron) in a Phase III outcomes trial in adults with type 2 diabetes and obesity or overweight at increased...

Roche laid out a new Phase III trial plan for Elevidys (delandistrogene moxeparvovec), aiming to address lingering European regulatory questions after prior trial performance issues. The company...

Revolution Medicines reported a survival benefit from a Phase III trial of daraxonrasib (RMC-6236), an investigational RAS-targeting therapy in metastatic pancreatic ductal adenocarcinoma. In the...

Gilead Sciences disclosed new patent information covering GTPase KRAS G12D mutant inhibitors designed for cancer treatment. The filing points to an extension of Gilead’s small-molecule oncology...

UCB agreed to buy Neurona for up to $1.2 billion, expanding its pipeline with a potentially one-off cell therapy for a form of epilepsy that remains difficult to treat. UCB’s deal comes as the...

Beeline Medicines launched with five programs licensed from Bristol Myers Squibb and secured a $300 million Series A led by Bain Capital. The company’s portfolio is built around therapies for...

The U.S. FDA accepted and granted priority review to Daiichi Sankyo and Merck & Co.’s B7-H3-directed antibody-drug conjugate, ifinatamab deruxtecan, for advanced extensive-stage small-cell lung...

Biopharma layoffs slowed year over year in Q1 2026, but total affected employees rose, largely driven by company-specific cut plans. BioSpace tallied 35 biopharma companies making or projecting...